Food allergies are a growing clinical problem leading to increased health care utilization and decreases in patient quality of life. Current treatment recommendations include strict dietary avoidance of the offending food as well as use of self-injectable epinephrine in case of accidental exposure with allergic reaction. Although many individuals will eventually outgrow their food allergies, a substantial number will not. Significant effort has been made to find novel treatments that protect patients from food-triggered reactions as well as to develop immune-modulating therapies that could lead to tolerance. In this review, three therapies that have shown the most promise for the treatment of food allergies are highlighted: oral immunotherapy, sublingual immunotherapy, and epicutaneous immunotherapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance
Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics. 2009;124:1549–55.
Patel DA, Holdford DA, Edwards E, Carroll NV. Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. J Allergy Clin Immunol. 2011;128:110–5.
Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy. 2010;65:933–45.
Boyce JAC, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(Suppl):S1–58.5.
Boyano-Martinez T, Garcia-Ara C, Pedrosa M, Diaz-Pena JM, Quirce S. Accidental allergic reactions in children allergic to cow’s milk proteins. J Allergy Clin Immunol. 2009;123:883–8.
Fleischer DM, Perry TT, Atkins D, Wood RA, Burks AW, Jones SM, et al. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics. 2012;130:e25–32.
Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to food. J Allergy Clin Immunol. 2001;107:191–3.
Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2008;122:1154–60.
Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D, La Rosa M, et al. Oral immunotherapy for cow’s milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105:376–81.
Martorell A, De la Hoz B, Ibanez I, Bone J, Terrados MS, Michavila A, et al. Oral desensitization as a useful treatment in 2-year-old children with cow’s milk allergy. Clin Exp Allergy. 2011;41:1297–304.
Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129:448–55.
Salmivesi S, Korppi M, Makela MJ, Paassilta M. Milk oral immunotherapy is effective in school-aged children. Acta Paediatr. 2013;102:172–6.
Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367:233–43. One of the first multicenter trials to demonstrate sustained unresponsiveness development following treatment with OIT.
Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the immune response. J Allergy Clin Immunol. 2011;127:654–60.
Blumchen K, Ulbricht H, Staden U, Dobberstein K, Beschorner J, de Camargo Lopes Oliveira L, et al. Oral peanut immunotherapy in children with peanut anaphylaxis. J Allergy Clin Immunol. 2010;126:83–91.
Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitization of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet. 2014;383:1297–304.
Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128:e9–e17.
Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrota A, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10:1.
Vickery BP, Scurlock AM, Kulis M, Steele PM, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133:468–75.
Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA, et al. Long-Term Treatment with Egg Oral Immunotherapy Enhances Sustained Unresponsiveness That Persists after Cessation of Therapy; JACI 2016: In press.
Caminiti L, Pajno GB, Crisafulli G, Chiera F, Collura M, Panasci G, et al. Oral immunotherapy for egg allergy: a double-blind placebo-controlled study, with postdesensitization follow-up. J Allergy Clin Immunol Pract. 2015;3:532–9.
Paassilta M, Salmivesi S, Mäki T, Helminen M, Korppi M. Children who were treated with oral immunotherapy for cows’ milk allergy showed long-term desensitization seven years later. Acta Paediatr 2015; in press. This study highlights the long-term effectiveness of treatment with OIT for milk allergy. Results indicate the OIT is effective long-term and that the side effect profile improves over time.
Keet CA, Seopaul S, Knorr S, Narisety S, Skripak JM, Wood RA. Long-term follow-up of oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2013;3:737–9.
Thyagarajan A, Jones SM, Calatroni A, Pons L, Kulis M, Woo CS, et al. Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children. Clin Exp Allergy. 2012;42:1197–205.
Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM. Peanut oral immuotherapy modifies IgE and IgG4 response to major peanut allergens. J Allergy Clin Immunol. 2013;131:128–34.
Begin P, Nadeau KC. Changes in peanut-specific T-cell clonotype with oral immunotherapy. J Allergy Clin Immunol. 2015;135:1636–8.
Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124:292–300.
Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, et al. Peanut oral immunotherapy results in increased antigen-induced regulator T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133:500–10.
Gorelik M, Narisety SD, Guerrerio AL, Chichester KL, Keet CA, Bieneman AP, et al. Suppression of the immunologic response to peanut during oral immunotherapy is often transient. J Allergy Clin Immunol. 2015;135:1283–92. This study provides insight into the mechanisms of OIT for peanut allergy, especially during desensitization. Although OIT is successful for desensitization and inducing sustained unresponsiveness, long-term tolerance remains elusive.
Vickery BP, Pons L, Kulis M, Steele P, Jones SM, Burks AW. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105:444–50.
Escudero C, Rodriguez del Rio P, Sanchez-Garcia S, Perez-Rangel I, Perez-Farinos N, Garcia-Fernandez C, et al. Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. Clin Exp Allergy. 2015;45:1833–43.
Kuitunen M, Englund H, Remes S, Moverare R, Pelkonen A, Borres MP, et al. High IgE levels to α-lactalbumin, β-lactoglobulin, and casein predict less successful cow’s milk oral immunotherapy. Allergy. 2015;70:955–62.
Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124:286–91.
Vickery BP, Scurlock AM, Steele P, Kamilaris J, Hiegel A, Carlisle S, et al. Early and persistent gastrointestinal side effects predict withdrawal from peanut oral immunotherapy (OIT) [abstract]. J Allergy Clin Immunol. 2011;126:AB87.
Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol. 2009;124:1351–2.
Elizur A, Goldberg MR, Levy MB, Nachshon L, Katz Y. Oral immunotherapy in cow’s milk allergic patients: course and long-term outcome according to asthma status. Ann Allergy Asthma Immunol. 2015;114:240–4.
Vazquez-Ortiz M, Alvaro M, Piquer M, Dominguez O, Machinena A, Martin-Mateos A, et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg-allergic children. Clin Exp Allergy. 2013;44:130–41.
Levy MB, Elizur A, Goldberg MR, Nachshon L, Katz Y. Clinical predictors for favorable outcome in an oral immunotherapy for IgE-mediated cow’s milk allergy. Ann Allergy Asthma Immunol. 2014;112:58–63. Identification of risk factors associated with adverse outcomes is important during OIT treatment. This study highlights several clinical factors that were associated with improved outcomes during OIT treatment for milk allergy.
Vazquez-Ortiz M, Alvaro-Lozano M, Alsina L, Garcia-Paba B, Piquer-Gilbert M, Giner-Munoz M, et al. Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test. Clin Exp Allergy. 2012;43:91–102.
Elizur A, Appel MY, Goldberg MR, Yichie T, Levy MB, Nachshon L, et al. Clinical and laboratory 2-year outcome of oral immunotherapy in patients with cow’s milk allergy. Allergy 2015; in press.
Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113:624–9. An important analysis regarding the development of EoE with food allergy treatment.
Brozek JL, Terracciano L, Hsu J, Kreis J, Compalati E, Santesso N, et al. Oral immunotherapy for IgE-mediated cow’s milk allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2012;42:363–74.
Fisher HR, du Toit G, Lack G. Specific oral tolerance induction in food allergic children: is oral desensitization more effective than allergen avoidance? a meta-analysis of published RCTs. Arch Dis Child. 2011;96:259–64.
Nurmatov U, Devereux G, Worth A, Healy L, Sheikh A. Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis. Br J Nutr. 2013;111:12–22.
Yeung JP, Kloda LA, McDevitt J, Ben-Shoshan M, Alizandehfar R. Oral immunotherapy for milk allergy. Cochrane Database Syst Rev 2012; CD009542.
Nowak-Wegrzyn A, Bloom KA, Sicherer SH, Shreffler WG, Noone S, Wanich N, et al. Tolerance to extensively heated milk in children with cow’s milk allergy. J Allergy Clin Immunol. 2008;122:342–7.
Lemon-Mule H, Sampson HA, Sicherer SH, Shreffler WG, Noone S, Nowak-Wegrzyn A. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol. 2008;122:977–83.
Kim JS, Nowak-Wegrzyn A, Sicherer SH, Noone S, Mosheir EL, Sampson HA. Dietary baked milk accelerates the resolution of cow’s milk allergy in children. J Allergy Clin Immunol. 2011;128:125–31.
Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127:1622–4.
Schneider LC, Rachid R, Lebovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132:1368–74.
Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol 2015; in press.
Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309–10.
Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: a systematic review and meta-analysis. Allergy. 2005;60:4–12.
Cox L. Sublingual immunotherapy for aeroallergens: status in the United States. Allergy Asthma Proc. 2014;35:34–42. A comprehensive review of SLIT with a focus on aeroallergens. Includes discussion of practical considerations that may impact the use of SLIT for food allergy.
Allam JP, Wurtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, et al. Phl p 5 resorption in human oral mucosa leads to a dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta 1 and IL-10 producing properties. J Allergy Clin Immunol. 2010;126:638–45.
Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. J Allergy Clin Immunol Pract. 2013;1:228–41.
Mempel M, Rakowski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: immunologic changes related to successful allergen immunotherapy. J Allergy Clin Immunol. 2007;119:507–8.
Kerzl R, Simonowa A, Ring J, Ollert M, Mempel M. Life-threatening anaphylaxis to kiwi fruit: protective sublingual allergen immunotherapy effect persists even after discontinuation. J Allergy Clin Immunol. 2007;119:507–8.
Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116:1073–9.
Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, de Alonso Diaz Durana MD, Garcia BE, Gonzalez-Mancebo E, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009;64:876–83.
Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131:119–27.
Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W, et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127:640–6.
Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock AM, et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;135:1240–8. Long-term follow-up of the first multicenter controlled trial for use of SLIT in the treatment of peanut allergy. Provides unique data regarding efficacy, adverse reactions, and efficacy.
Makatsori M, Scadding GW, Lombardo C, Bisoffi G, Ridolo E, Durham SR, et al. Dropouts in sublingual allergen immunotherapy trials—a systematic review. Allergy. 2014;69:571–80.
Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers’ viewpoint. J Allergy Clin Immunol. 2010;126:668–9.
Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135:1275–82. An excellent, randomized study with direct comparison between SLIT and OIT. Results included efficacy, development of sustained unresponsiveness, and associated immunologic changes.
Benhamou PH, Dioszeghy V, Puteaux E, Ligouis M, Dhelft V, Plaquet C, et al. Long-term protection against new sensitization after milk-EPIT in mice sensitized to milk is mediated by Tregs [abstract]. J Allergy Clin Immunol. 2014;133(Suppl):AB47.
Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Plaquet C, et al. Epicutaneous immunotherapy-induced regulatory T cells could migrate to more various sites of allergen exposure compared to sublingual or subcutaneous immunotherapy in mice sensitized to peanut [abstract]. J Allergy Clin Immunol. 2014;133(Suppl):AB48.
Dioszeghy V, Mondoulet L, Dhelft V. Protection from oral peanut-induced esophageal lesions in sensitized mice treated by epicutaneous immunotherapy is mediated by CD25 + CD4+ Tregs [abstract]. J Allergy Clin Immunol. 2012;129:AB114.
Dioszeghy V, Mondoulet L, Dhelft V. Long-term maintenance of regulator T cells induced by specific epicutaneous vs sublingual immunotherapy in mice sensitized to peanut [abstract]. J Allergy Clin Immunol. 2013;68:S97.
Mondoulet L, Tost J, Puteaux E, Ligouis M, Dhelft V, Benhamou PH. Epigenetic changes following epicutaneous immunotherapy in peanut sensitized mice [abstract]. J Allergy Clin Immunol. 2015;135.
Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH. Cow’s milk epicutanous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125:1165–7.
Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using Viaskin® patch. JACI 2016: In press.
Dupont C, Bourrier T, de Blay F, Guenard-Bibault L, Sauvage C, Cousin M-O, et al. Peanut epicutanous immunotherapy (EPIT) in peanut-allergic children: 18 months treatment in the ARACHILD study [abstract]. J Allergy Clin Immunol. 2014;133(Suppl):AB102.
Sampson HA, Agbotounou W, Thebault C, Ruban C, Martin L, Sussman GL, et al. Enhanced efficacy and confirmed safety of a two-year epicutaneous immunotherapy (EPIT) treatment of peanut allergy with Viaskin® peanut: the continuation of the Vipes Phase IIb randomized controlled trial (RCT) [abstract]. J Allergy Clin Immunol. 2016;137:AB408.
Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256–62.
Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99:744–51.
Li XM, Srivastava K, Grishin A, Huang CK, Schofield B, Burks AW, et al. Persistent protective effect of heat-killed Escherichia coli producing “engineered”, recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol. 2003;112:159–67.
Li XM, Srivastava K, Huleatt JW, Bottomly K, Burks AW, Sampson HA. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol. 2003;170:3289–95.
Li X, Huang CK, Schofield BH, et al. Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol. 1999;162:3045–52.
Srivastava K, Li XM, Bannon GA, et al. Investigation of the use of ISS-linked Ara h2 for the treatment of peanut-induced allergy. J Allergy Clin Immunol. 2001;107(suppl):S233.
Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R, et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 2013;68:803–8.
Bauer RN, Manohar M, Singh AM, Jay DC, Nadeau KC. The future of biologics: applications for food allergy. J Allergy Clin Immunol. 2015;135:312–23. An excellent, comprehensive review of various biologics used in food allergy. Included is a review of immunologic changes associated with food allergy that is useful for understanding the approaches for food allergy treatment.
Senti G, Kundig TM. Intralymphatic immunotherapy. World Allergy Organ J. 2015;8:9.
Conflict of Interest
Dr. Pesek declares no conflict of interest. Dr. Jones reports grants from NIH-NIAID, FARE-Food Allergy Research Education, Allergy Research Corporation, DBV Technologies, and National Peanut Board; personal fees from FARE-Food Allergy Research Education, Stallergenes, Kansas City Allergy Society, Mercy Children’s Hospital, Riley Children’s Hospital, Southwestern Medical School-Children’s Medical Center, European Academy of Allergy & Clinical Immunology; New York Allergy & Asthma Society; Iowa Society of Allergy, Asthma & Immunology, and University of Iowa, Paul M. Seebohm Lectureship in Allergy.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on Food Allergy
About this article
Cite this article
Pesek, R.D., Jones, S.M. Current and Emerging Therapies for IgE-Mediated Food Allergy. Curr Allergy Asthma Rep 16, 28 (2016). https://doi.org/10.1007/s11882-016-0610-0
- Oral immunotherapy
- Sublingual immunotherapy
- Epicutaneous immunotherapy
- Food allergy